The new prophylactic strategy for colitic cancer in inflammatory bowel disease by modulating microbiota

Abstract

It is well understood that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD). In addition, IBD patients are well known to have a higher risk of developing colitic cancer due to chronic inflammation. Recent evidence suggests that manipulation of microbiota improves the clinical outcome of patients with IBD and may reduce onset of colitic cancer without obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD and colitic cancer, and the nutraceutical therapy for colitic cancer.

Key Words::

• colitic cancer
• inflammatory bowel disease
• microbiota
• nutraceutical
• SLC5A8
• toll-like receptor 4

Acknowledgment

The authors would like to thank Ms Noriko Kuriyama (Kirin Holding Co.) for checking manuscript, and Ms Iku Owada (Kirin Holding Co.) for her kind support.

Declaration of interest: The authors state no conflict of interest.